logo
Pheasants Forever and Quail Forever president and CEO to speak at UND event

Pheasants Forever and Quail Forever president and CEO to speak at UND event

Yahoo18-04-2025
Apr. 18—When scientists communicate their work to a lay audience, they often load up with facts and figures that might not resonate with people outside their profession.
It's no different with the biologists who work for Pheasants Forever and Quail Forever, says Marilyn Vetter of New Richmond, Wisconsin, president and CEO of Pheasants Forever and Quail Forever.
"If you talk to the wildlife biologists on the team, they're going to be the first ones to admit that, just like anybody that majors in biology or engineering, they love the facts behind things," Vetter said in an interview. "The science is inherently what drives them.
"Sometimes, when you have that mindset, it's hard to understand why others don't get inspired by hearing just the facts. For most people that are not in the career, it's hard to get attached emotionally to the facts."
Therein lies the dilemma when communicating science.
Vetter, who grew up near Anamoose, North Dakota, and graduated from UND in 1988 with a major in communications and a minor in political science, will highlight the challenge — and how to overcome it — at noon Friday, April 25, as keynote speaker for the 2025 Glenn Allen Paur Lecture Series.
Vetter's topic for this year's Paur Lecture is "Science and Storytelling: How Leaders Can (and should) Create Excitement for Wildlife Conservation." The lecture, which is free and open to the public, will be held in Chester Fritz Library Room 406.
"It's super important for those that are doing research or deploying research to figure out, 'How do they use what inspires them to inspire others through means that make it more approachable, that are more in layman's terms,' " Vetter said. "If they come out and do a lecture on the science behind bird nesting behavior or habitat, that's probably going to be difficult for most people to embrace unless they're already interested in the actual facts behind it.
"What I'm suggesting is, if we want good science to win, we have to find a way for people to hear (the facts) so they get to experience two things: They get to experience that emotional connection to the story, and it's based on fact."
The UND Chapter of The Wildlife Society hosts the annual lecture series in honor of Glenn Allen Paur, a UND biology graduate from Pisek, North Dakota, who drowned in a May 1978 boating accident while assisting a UND professor with a research project on Leech Lake.
The Paur family established the Lecture Series and the Glenn Allen Paur Memorial Scholarship in 1979 in his honor and memory.
The series has featured a variety of notable speakers, including
Steve Williams,
a 1981 UND master's degree graduate and former director of the U.S. Fish and Wildlife Service, in 2022;
David Bjerklie,
a 1976 UND graduate and renowned science communicator, in 2023; and, in 2024,
Chuck Black,
a 2010 UND graduate and wildlife artist now living in Belgrade, Montana, who won the 2023 Federal Duck Stamp Art Contest.
That puts Vetter in some lofty company.
"Believe me, I went back and looked, and I'm like, 'Wow, those are some big shoes to fill,' " she said. "The folks that have preceded me, it's a small group and some really important people that have made a huge difference in conservation.
"I'm certainly more than humbled and honored to be part of that."
Vetter, who became president and CEO of PF and QF in February 2023, says communicating about conservation can be especially challenging on social media, where "the sexy story is what sells in headlines."
"It is very hard for people that have the science behind them to break through on those platforms if they can't find a way to either tell (the story) through a shorter version of the words that create a more emotional connection or through video, to break through all of that clutter," she said.
"And if we don't find a way to break through, then the facts will get left behind, and the facts are really what creates urgency and a compelling story around conservation and everything else."
Video has proven to be the most effective way for Pheasants Forever and Quail Forever to tell their stories, Vetter says.
"Even if it's just the person (telling) the story in the video, because that is how people digest news anymore on social media," she said. "It's fascinating to watch how our corporate sponsors or how agency partners and others come to us and say, 'Well, we'd love to support this initiative, but we'd sure love to have a video to tell the story afterwards.'
"They know that's how people are digesting and internalizing the news."
A perfect example of social media success is "Pheasant Fact Friday," Vetter says. The weekly educational series, which includes snippets of info about pheasants and quail, posts Friday afternoons on the PF and QF Facebook and Instagram pages.
People have embraced the pheasant and quail nuggets, she said.
"I can tell you, I have learned a lot about pheasants and quail in the last however many months we've been promoting Pheasant Fact Friday and its sister in the quail space," Vetter said. "It has made (the information) digestible enough that people are learning in bite-sized snacks. And over a year, they're learning a ton of information in a way that they can remember it."
Before taking the helm of Pheasants Forever and Quail Forever, Vetter says she hadn't been back on the UND campus in several years. In April 2023, Vetter was the keynote speaker at UND's Women for Philanthropy Luncheon and says she's looking forward to returning to campus for the Paur Lecture.
"It's so powerful to come back and see that campus and how it has flourished," Vetter said. "It was a remarkable place for me to go to school, and it changed my world. I grew up on a cattle ranch, and my bubble was the size of a postage stamp, and I remember coming to campus and thinking, 'Wow, this place is huge.'
"I love that I get to come back to campus in a way that's more aligned with my new role and that I get to spend time with students in the wildlife biology arena and watch, just how they're thinking about the future in this space. It's pretty remarkable, and I'm really excited."
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Innospera Pharma Appoints Dr. Glenn Crater as Chief Medical Officer to Support Advancement of ING-006 Toward the Clinic
Innospera Pharma Appoints Dr. Glenn Crater as Chief Medical Officer to Support Advancement of ING-006 Toward the Clinic

Business Wire

time09-06-2025

  • Business Wire

Innospera Pharma Appoints Dr. Glenn Crater as Chief Medical Officer to Support Advancement of ING-006 Toward the Clinic

MONTREAL--(BUSINESS WIRE)-- Innospera Pharma Inc. ('Innospera'), a private, near-clinical-stage biotechnology company advancing differentiated small molecule modulators of GPR84 and GPR40 to treat inflammatory and metabolic diseases, today announced the appointment of Dr. Glenn Crater, MD, FCCP as Chief Medical Officer (CMO). Glenn will start immediately as a fractional CMO, with the commitment to joining full time as the Company's lead compound reaches the clinic. A board-certified pulmonologist, Dr. Crater has played pivotal roles in advancing respiratory drug candidates, with particular expertise in Idiopathic Pulmonary Fibrosis (IPF) — the initial target indication for Innospera's lead compound, ING-006 Share Dr. Crater brings to Innospera over 25 years of clinical, regulatory, and leadership experience in pulmonary medicine and drug development. A board-certified pulmonologist, Dr. Crater has played pivotal roles in advancing respiratory drug candidates, with particular expertise in Idiopathic Pulmonary Fibrosis (IPF) — the initial target indication for Innospera's lead compound, ING-006, which is poised to enter clinical development in the near future. 'We are thrilled to welcome Glenn to Innospera at this critical moment in our growth,' said François Ravenelle, PhD, Chief Executive Officer of Innospera. 'Having worked closely with Glenn at Inversago Pharma, I've witnessed first-hand his commitment to scientific rigor, clinical excellence, and patient impact. His deep understanding of IPF and drug development will be invaluable as we initiate clinical studies for ING-006 and build a pipeline of novel GPR84/GPR40 modulators.' Prior to joining Innospera, Dr. Crater served as Chief Medical Officer at multiple biotechnology companies and held senior medical leadership positions across both private and public firms, contributing to successful regulatory submissions and clinical programs in respiratory and fibrotic diseases. 'I'm excited to reunite with François and the team at Innospera,' said Dr. Crater. 'ING-006 represents a promising new approach to modulating inflammation and fibrosis via GPCR lipid signaling. I look forward to advancing this program in the clinic and working to deliver transformative therapies for patients living with IPF and related diseases.' About Innospera Pharma Innospera is a Montreal-based biotechnology company developing first-in-class GPR84 and GPR40 modulators to restore homeostasis in diseases driven by metabolic and inflammatory dysfunction. The company's lead compound, ING-006, is a synthetic lipid designed to address Idiopathic Pulmonary Fibrosis (IPF) by resolving inflammation and reducing fibrogenesis. Innospera is backed by a strong syndicate of investors including Investissement Québec, Seido Capital, and Anges Québec. For more information, visit

Slingshot Biosciences Appoints Glenn Bilawsky as CEO to Lead Strategic Expansion across Clinical Trial and Diagnostic Markets
Slingshot Biosciences Appoints Glenn Bilawsky as CEO to Lead Strategic Expansion across Clinical Trial and Diagnostic Markets

Business Wire

time28-05-2025

  • Business Wire

Slingshot Biosciences Appoints Glenn Bilawsky as CEO to Lead Strategic Expansion across Clinical Trial and Diagnostic Markets

EMERYVILLE, Calif.--(BUSINESS WIRE)--Slingshot Biosciences, a leader in precision-engineered cell mimics, has appointed Glenn Bilawsky as Chief Executive Officer. He succeeds Founder and former CEO Jeffrey Kim, PhD, who will remain actively involved as a Senior Advisor and Board Director. This transition is a strategic inflection point as Slingshot scales to meet rising global demand for cell mimics as standardized, reliable alternatives to biological controls. The widespread adoption of its TruCytes™ and SpectraComp ® products across research, clinical trials, diagnostics, and cell therapy applications is driving the company to expand its commercial footprint, industry partnerships, and advance regulatory-grade solutions. 'Slingshot is transforming how scientists in diagnostic, and therapeutic research and development access and apply cellular controls,' said Glenn Bilawsky, CEO. 'Jeff has built a remarkable company rooted in scientific excellence. I'm excited to build on that foundation—scaling the commercial team and focusing our portfolio to ensure our solutions maintain their position as the gold standard of cell-based controls used in regulated and research workflows.' Bilawsky brings decades of success and leadership in scaling life science, contract research, and analytical laboratory service companies focused on biomarker development. His appointment will accelerate Slingshot's momentum and the achievement of its mission to replace traditional biological reference materials with scalable, customizable and cost-effective cell mimic controls. Dr. Kim, who invented and led the development of Slingshot's core technologies, emphasized continuity in the company's mission: 'I'm proud of how far Slingshot has come. Glenn brings a remarkable track record of success and his leadership will unlock our next phase of growth. I am committed to the continued support of the company and look forward to working with Glenn in this next phase of the business.' About Slingshot Biosciences Slingshot Biosciences develops cell mimics for a range of applications in diagnostics and therapeutics. Slingshot leverages advances in distributed manufacturing, engineering, and polymer chemistry to provide an industry-first, off-the-shelf customizable solution for cell-like reagents that are stable and targeted toward a range of indications and markets.

Slingshot Biosciences Appoints Glenn Bilawsky as CEO to Lead Strategic Expansion across Clinical Trial and Diagnostic Markets
Slingshot Biosciences Appoints Glenn Bilawsky as CEO to Lead Strategic Expansion across Clinical Trial and Diagnostic Markets

Yahoo

time28-05-2025

  • Yahoo

Slingshot Biosciences Appoints Glenn Bilawsky as CEO to Lead Strategic Expansion across Clinical Trial and Diagnostic Markets

EMERYVILLE, Calif., May 28, 2025--(BUSINESS WIRE)--Slingshot Biosciences, a leader in precision-engineered cell mimics, has appointed Glenn Bilawsky as Chief Executive Officer. He succeeds Founder and former CEO Jeffrey Kim, PhD, who will remain actively involved as a Senior Advisor and Board Director. This transition is a strategic inflection point as Slingshot scales to meet rising global demand for cell mimics as standardized, reliable alternatives to biological controls. The widespread adoption of its TruCytes™ and SpectraComp® products across research, clinical trials, diagnostics, and cell therapy applications is driving the company to expand its commercial footprint, industry partnerships, and advance regulatory-grade solutions. "Slingshot is transforming how scientists in diagnostic, and therapeutic research and development access and apply cellular controls," said Glenn Bilawsky, CEO. "Jeff has built a remarkable company rooted in scientific excellence. I'm excited to build on that foundation—scaling the commercial team and focusing our portfolio to ensure our solutions maintain their position as the gold standard of cell-based controls used in regulated and research workflows." Bilawsky brings decades of success and leadership in scaling life science, contract research, and analytical laboratory service companies focused on biomarker development. His appointment will accelerate Slingshot's momentum and the achievement of its mission to replace traditional biological reference materials with scalable, customizable and cost-effective cell mimic controls. Dr. Kim, who invented and led the development of Slingshot's core technologies, emphasized continuity in the company's mission: "I'm proud of how far Slingshot has come. Glenn brings a remarkable track record of success and his leadership will unlock our next phase of growth. I am committed to the continued support of the company and look forward to working with Glenn in this next phase of the business." About Slingshot Biosciences Slingshot Biosciences develops cell mimics for a range of applications in diagnostics and therapeutics. Slingshot leverages advances in distributed manufacturing, engineering, and polymer chemistry to provide an industry-first, off-the-shelf customizable solution for cell-like reagents that are stable and targeted toward a range of indications and markets. View source version on Contacts Brint Rodenpr@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store